Skip to content
Aminoscope
← Research
GLP-1

Retatrutide vs tirzepatide vs semaglutide: the three-way, read honestly

One, two, three receptors — and roughly 15%, 21% and 24% weight loss. The mechanism ladder is real, but two drugs are approved and one is still investigational, and none were compared in the same trial.

Julian Roth6 min read
MEAN WEIGHT LOSS AT TOP DOSE−14.9%−20.9%−24.2%semaglutidetirzepatideretatrutideSTEP 1 · approvedSURMOUNT-1 · approvedPhase 2 · investigational1 receptor2 receptors3 receptorscross-trial · not head-to-head
Need a closer look?Enlarge illustration

Semaglutide, tirzepatide and retatrutide activate different combinations of metabolic receptors. That helps explain their mechanisms, but receptor count does not rank treatments. Semaglutide and tirzepatide have approved uses; retatrutide now has published Phase 3 evidence and remains investigational. Compare the trial populations and analysis methods alongside each percentage.

The mechanism ladder, rung by rung

The three agents differ by how many incretin-and-metabolic receptors a single peptide activates. Semaglutide is a GLP-1 receptor mono-agonist: one pathway, driving appetite suppression and insulin secretion. Tirzepatide adds the GIP receptor, making it a dual agonist — the extra incretin arm is the mechanistic reason many expected it to outperform semaglutide, a question taken up in our tirzepatide vs semaglutide review. Retatrutide adds a third target, the glucagon receptor, which is thought to raise energy expenditure and mobilize hepatic fat on top of the two incretin effects. Each added rung is a plausible reason to expect more weight loss — but mechanism predicts the direction of an effect, not its size.

The three headline numbers

In STEP 1, once-weekly semaglutide 2.4 mg produced a mean weight loss of about 14.9% at 68 weeks in adults with obesity and without diabetes.[1] In SURMOUNT-1, tirzepatide at 15 mg reached roughly 20.9% at 72 weeks in a comparable population.[2] In the retatrutide Phase 2 obesity trial, 338 adults received the triple agonist or placebo, and the 12 mg dose produced about 24.2% mean weight loss at 48 weeks.[3] The ordering matches the mechanism ladder exactly — which is satisfying, and also the reason to be careful. A neat pattern is easy to over-read.

Why this is not a fair three-way race

Those three figures come from three different studies, run in different people, over different durations, at different phases of development. STEP 1 ran 68 weeks; SURMOUNT-1 ran 72; the retatrutide trial ran 48 and, notably, had not clearly plateaued when it ended — a detail we unpack in the retatrutide clinical evidence review. Baseline weights, trial designs and dropout handling all differ. Lining the bars up side by side suggests the ranking is right; it does not prove the magnitudes are directly comparable.

TRIUMPH-1 is now published: its 80-week treatment-regimen estimate at 12 mg was −25.0% versus −3.9% with placebo.[6] This analysis differs from efficacy-estimand sponsor headlines. TRIUMPH-5 has completed enrollment, but the sources checked do not establish completed comparison results.[8] Until then, separate-trial percentages cannot prove superiority for an individual patient.

The three-way at a glance

Swipe to see all columns

Three separate trials, not one head-to-head study. The weight-loss figures track the mechanism ladder but are not directly comparable across trials.
SemaglutideTirzepatideRetatrutide
MechanismGLP-1 (mono-agonist)GIP + GLP-1 (dual)GIP + GLP-1 + glucagon (triple)
Receptors targeted123
Headline weight loss≈ 14.9% (STEP 1)≈ 20.9% (SURMOUNT-1)≈ 24.2% in historical Phase 2; see published Phase 3 update
Trial phase & lengthPhase 3 · 68 wkPhase 3 · 72 wkPhase 2 (48 wk, n=338); published Phase 3 also available
Regulatory statusFDA-approvedFDA-approvedInvestigational — not approved
Dosing routeOnce-weekly injectableOnce-weekly injectableOnce-weekly injectable
Available now?YesYesNo
Three separate trials, not one head-to-head study. The weight-loss figures track the mechanism ladder but are not directly comparable across trials. STEP 1 (PMID 33567185); SURMOUNT-1 (PMID 35658024); retatrutide Phase 2 (PMID 37366315); retatrutide Phase 3 TRIUMPH-1 topline (Lilly news release, May 2026).

What the drugs share

For all their differences, the three have a family resemblance. All are once-weekly subcutaneous injectables, and all share the incretin-class tolerability profile: nausea, vomiting and diarrhea that are common, dose-related and typically managed by slow dose escalation. The one head-to-head fact anywhere in this trio is between the two approved drugs — SURMOUNT-5 randomized tirzepatide against semaglutide at obesity doses and found tirzepatide produced greater weight loss.[4] TRIUMPH-5 compares retatrutide with tirzepatide, but no completed results were established in this check, which is exactly why the retatrutide vs tirzepatide comparison stays cross-trial. Until it reaches US pharmacies, the weight-loss drugs you can actually be prescribed are semaglutide and tirzepatide; the Belle review covers a flat monthly price that stays the same at every dose.

The honest bottom line

The mechanism comparison is useful; a clinical ranking requires stronger evidence. Retatrutide’s published Phase 3 results extend its early record, but separate trials cannot settle superiority. Semaglutide and tirzepatide have approved treatment pathways. The right choice also depends on indication, contraindications, tolerability, access and a clinician’s assessment.

Reviewed against primary sources by the Aminoscope desk

Sources

  1. [1] Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185
  2. [2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PMID 35658024
  3. [3] Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. PMID 37366315
  4. [4] Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PMID 40353578
  5. [5] Eli Lilly and Company. (2026). Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline results, ~28.3% at 80 weeks). investor.lilly.com (news release, May 21, 2026). Source
  6. [6] Jastreboff AM, Kaplan LM, Davies MJ, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. PMID 42814954
  7. [7] Eli Lilly and Company (2026). Expanded access — eligibility, physician requests and regulatory permission. Lilly. Source
  8. [8] Eli Lilly and Company (2026). TRIUMPH-5 (NCT06662383): retatrutide compared with tirzepatide — completed enrollment. Lilly Trials. Source

Where to get it

Best tirzepatide providers

Compare the telehealth services that prescribe compounded or branded tirzepatide, on price transparency and clinical oversight.

Compare providers →

Related tool

GLP-1 weight-loss comparison

See semaglutide, tirzepatide, retatrutide and the pipeline ranked by mean trial weight loss — every figure traced to its source.

More in GLP-1